Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
WALTHAM, Mass., Jan. 03, 2018 -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the 10th Annual Biotech Showcase 2018 Conference at the Hilton San Francisco Union Square on Monday, January 8 at 11:00 a.m. (Pacific). A live webcast will be available on the investor relations page at www.NeuroMetrix.com and will be archived after the event. Dr. Gozani will also present at the Digital Medicine & Medtech Showcase on Tuesday, January 9 at 1:00 p.m. (Pacific) which will not be webcast. Both talks will highlight the Company's Quell® Wearable Pain Relief Technology™ and provide an update on the Company’s business activities.
About Quell
Quell is an advanced, wearable technology for treating chronic pain. It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with the Quell Health Cloud, which provides customized feedback and powers one of the world’s largest chronic pain databases. Quell is available online and through select retailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital health to address chronic health conditions including chronic pain, diabetes, and sleep disorders. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
[email protected]
Source: NeuroMetrix, Inc.
